296 assets in Myelodysplastic Syndrome

Therapeutic assets addressing Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Olutasidenib Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	B (62)
Plerixafor Myelodysplastic Syndrome	Stanford University	P2	B (62)
Ruxolitinib Myelodysplastic Syndrome	Center for International Blood and Marrow Transplant Research	P2	B (62)
Thioguanine Anhydrous Myelodysplastic Syndrome	Children's Oncology Group	P3	B (62)
Valproic Acid Myelodysplastic Syndrome	Haukeland University Hospital	P2	B (62)
(+)-Vincristine Myelodysplastic Syndrome	Andrew E. Place, MD	P2	B (62)
Bortezomib Myelodysplastic Syndrome	Indiana University	P2	B (61)
Diphenhydramine Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P2	B (61)
Midostaurin Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2/3	B (61)
Bendamustine Myelodysplastic Syndrome	St. Petersburg State Pavlov Medical University	P2	B (60)
Hydroxyurea Myelodysplastic Syndrome	University Hospital Tuebingen	P3	B (60)
Mesna Myelodysplastic Syndrome	Center for International Blood and Marrow Transplant Research	P2	B (60)
Mylotarg Myelodysplastic Syndrome	Vor Biopharma	P2/3	B (60)
Nerofe Myelodysplastic Syndrome	Immune System Key Ltd	P2	B (60)
Olaparib Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	B (60)
Orca-T Myelodysplastic Syndrome	Orca Biosystems, Inc.	P3	B (60)
Palifermin Myelodysplastic Syndrome	City of Hope Medical Center	P2	B (60)
Pevonedistat Myelodysplastic Syndrome	University of Leipzig	P3	B (60)
RVU120 Myelodysplastic Syndrome	Ryvu Therapeutics SA	P2	B (60)
Venetoclax Myelodysplastic Syndrome	National Cancer Institute (NCI)	P3	B (60)
Zanubrutinib Myelodysplastic Syndrome	Medical College of Wisconsin	P2	B (60)
Epoetin Alfa Myelodysplastic Syndrome	National Cancer Institute (NCI)	P3	B (59)
Luspatercept Myelodysplastic Syndrome	National Cancer Institute (NCI)	P3	B (59)
Abatacept Recombinant Myelodysplastic Syndrome	Center for International Blood and Marrow Transplant Research	P3	B (58)
Allogeneic Human Umbilical Cord Blood Myelodysplastic Syndrome	Leland Metheny	P2	B (58)
Allopurinol Myelodysplastic Syndrome	Masonic Cancer Center, University of Minnesota	P2	B (58)
Enasidenib Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	B (58)
Fentanyl Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P2	B (58)
Nadravaleucel Myelodysplastic Syndrome	David Wald	P2	B (58)
Selinexor Myelodysplastic Syndrome	Institute of Hematology & Blood Diseases Hospital, China	P2	B (58)
Sorafenib Myelodysplastic Syndrome	St. Petersburg State Pavlov Medical University	P2	B (58)
Alpha-Interferon Myelodysplastic Syndrome	Peking University People's Hospital	P2	B (57)
Astarabine Myelodysplastic Syndrome	BioSight Ltd.	P2	B (57)
Eltanexor Myelodysplastic Syndrome	Vanderbilt-Ingram Cancer Center	P1/2	B (57)
Ganciclovir Myelodysplastic Syndrome	City of Hope Medical Center	P2	B (57)
Ipilimumab Myelodysplastic Syndrome	OHSU Knight Cancer Institute	P2	B (57)
Vorinostat Myelodysplastic Syndrome	OHSU Knight Cancer Institute	P2	B (57)
Vyxeos Myelodysplastic Syndrome	University of Birmingham	P2/3	B (57)
Zoledronate Myelodysplastic Syndrome	University of Wisconsin, Madison	P2	B (57)
Ivosidenib Myelodysplastic Syndrome	Ruijin Hospital	P2	B (56)
Avastinib Myelodysplastic Syndrome	Ruijin Hospital	P2/3	CCC (55)
Emavusertib Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	CCC (55)
Gilteritinib Myelodysplastic Syndrome	National Cancer Institute (NCI)	P2	CCC (55)
Hpc, Cord Blood Myelodysplastic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Ruxolitinib Phosphate Myelodysplastic Syndrome	City of Hope Medical Center	P2	CCC (55)
Allogeneic Cd8+ Leukemia-Associated Antigens Specific T Cells Nexi-001 Myelodysplastic Syndrome	City of Hope Medical Center	P1/2	CCC (54)
Bemcentinib Myelodysplastic Syndrome	BerGenBio ASA	P2	CCC (54)
Edetate Calcium Disodium Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CCC (54)
Leuporelin Myelodysplastic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (54)
Treg Cells Myelodysplastic Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (54)

Showing 51 to 100 of 296 assets

PreviousPage 2 of 6Next